Hikma Pharmaceuticals PLC
HIK.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 22.39 | -0.41 | -30.15 |
| FCF Yield | 7.18% | 8.67% | 9.34% | 7.11% |
| EV / EBITDA | 8.49 | 7.65 | 10.74 | 9.89 |
| Quality | ||||
| ROIC | 12.79% | 7.16% | 14.56% | 14.91% |
| Gross Margin | 45.25% | 48.94% | 50.26% | 50.96% |
| Cash Conversion Ratio | 1.57 | 3.20 | 2.82 | 1.52 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.50% | 4.04% | 2.45% | 4.97% |
| Free Cash Flow Growth | -9.11% | 11.99% | -20.49% | 68.84% |
| Safety | ||||
| Net Debt / EBITDA | 1.42 | 1.25 | 2.09 | 0.56 |
| Interest Coverage | 8.16 | 4.08 | 7.68 | 15.57 |
| Efficiency | ||||
| Inventory Turnover | 1.74 | 1.65 | 1.61 | 1.80 |
| Cash Conversion Cycle | 239.53 | 244.88 | 254.07 | 237.89 |